Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone
A solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, are useful as BTK inhibitors.
1. A solid form of compound 1,
wherein said solid form is a crystalline form A2,
wherein said form A2 is characterized by a crystal form, having a monoclinic space group P2 1 with the lattice parameters (at 200 K) a=9.4±0.1 Å, b=37.2±0.2 Å, c=12.8±0.1 Å, and β=91.9±0.5° (with α=γ=90°).
2. The solid form of claim 1 , characterized as a mixture of crystalline forms A1 and A2; wherein said crystalline form A1 is characterized by a crystal form, having a monoclinic space group P2 1 with the lattice parameters (at 200 K) a=12.8±0.1 Å, b 9.4±0.1 Å, c=37.3±0.2 Å, and β=98.5±0.5° (with α=γ=90°).
3. A pharmaceutical composition, comprising:
the solid form of compound 1 of claim 1 , and
a pharmaceutically acceptable adjuvant, carrier, or vehicle.
4. A method for treating a BTK-mediated disorder in a patient in thereof, comprising:
administering to said patient a solid form of compound 1 of claim 1 ;
wherein said BTK-mediated disorder is systemic lupus erythematosus (SLE), multiple sclerosis, or rheumatoid arthritis.
5. A pharmaceutical composition, comprising:
a solid form of compound 1 of claim 2 , and
a pharmaceutically acceptable adjuvant, carrier, or vehicle.
6. A method for treating a BTK-mediated disorder in a patient in need thereof, comprising:
administering to said patient a solid form of compound 1 of claim 2 ;
wherein said BTK-mediated disorder is systemic lupus erythematosus (SLE), multiple sclerosis, or rheumatoid arthritis.